Quote | Enveric Biosciences Inc Com (NASDAQ:ENVB)
Last: | $0.52 |
---|---|
Change Percent: | -5.83% |
Open: | $0.5533 |
Close: | $0.5522 |
High: | $0.5533 |
Low: | $0.5112 |
Volume: | 56,884 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Enveric Biosciences Inc Com (NASDAQ:ENVB)
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...
Message Board Posts | Enveric Biosciences Inc Com (NASDAQ:ENVB)
Subject | By | Source | When |
---|---|---|---|
Nice flipper | PennyPusher786 | investorshub | 05/18/2023 7:25:40 PM |
Ok it cooled off Five dollar run | Triple nickle | investorshub | 05/18/2023 5:44:17 PM |
Now a Rug Pooool candidate lol... Now it's | PennyPusher786 | investorshub | 05/18/2023 4:42:49 PM |
Another rip or another dump, only the devil knows | PennyPusher786 | investorshub | 05/18/2023 3:53:22 PM |
Good call. Ran to 4.20s and dumped to 3.20s | PennyPusher786 | investorshub | 05/18/2023 3:52:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Enveric Biosciences Inc Com Company Name:
ENVB Stock Symbol:
NASDAQ Market:
Enveric Biosciences Inc Com Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Com...